PO.IM01.04 · 免疫学
HIV感染者中与牙周病及口腔癌风险相关的炎症小体依赖性和非依赖性失调
Inflammasome dependent and independent dysregulation associated with periodontal disease and oral cancer risk in people with HIV
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:HIV感染者(PWH)表现出免疫失调,这会增加其对牙周病(PD)的易感性,从而升高慢性口腔炎症、组织损伤和肿瘤发生的风险。持续性牙周炎可能通过致病菌流行率升高和炎性细胞因子水平升高,驱动口腔鳞状细胞癌(OSCC)的发生。事实上,我们的初步数据显示,与PD相关的口腔微生物组存在生态失调。此外,PD可能与炎症小体功能障碍相关,从而影响下游细胞因子的产生。在PWH中,这些炎症过程可能加剧,助长促肿瘤发生的微环境。本研究旨在量化PWH中炎症小体和炎症标志物的水平,并评估其与PD和OSCC风险的关联。
方法:从202名病毒学抑制的PWH中采集唾液和口腔漱液样本,以及社会人口学和临床数据。进行了全面的牙周评估,并根据PD严重程度将参与者分为四组:无、轻度、中度和重度。使用ELISA量化唾液中炎症小体(NLRP3和NLRC4)的蛋白水平,使用ELLA量化细胞因子浓度(IL-1beta、IL-4、IL-6、IL-8、IL-10、IL-17A和TNF-alpha)。使用R统计软件进行统计分析。使用Mann-Whitney或Kruskal-Wallis检验并进行事后校正来比较中位数值。
结果:患有PD的参与者表现出显著更高水平的IL-1beta(400 pg/mL vs 235 pg/mL,p<0.01)、IL-6(25.4 pg/mL vs 14.2 pg/mL,p<0.01)和IL-8(798 pg/mL vs 549 pg/mL,p=0.04),同时IL-17水平呈升高趋势(2.01 pg/mL vs 1.50 pg/mL,p=0.05)。此外,与无PD者(235 pg/mL)相比,中度(408 pg/mL,p=0.01)和重度PD(378 pg/mL,p=0.01)受试者的IL-1beta显著更高。另一方面,虽然NLRP3和NLRC4水平在不同PD状态之间无显著差异,但与中度(5.83 ng/mL,p<0.01)或无PD(5.71 ng/mL,p=0.02)相比,重度PD者(3.37 ng/mL)的NLRP3水平显著更低。
结论:炎性细胞因子(尤其是IL-1B)水平升高,且炎症小体水平随PD严重程度而改变,支持细胞焦亡在PD发病机制中的作用。额外的非焦亡依赖性炎性细胞因子的慢性升高以及口腔微生物组的生态失调可能促成持续性炎症微环境,与PWH中OSCC风险增加相关。这些结果强调了监测口腔细胞因子谱作为疾病进展生物标志物以及PWH癌症风险潜在指标的重要性。
查看英文原文 English abstract
Introduction : People with HIV (PWH) exhibit immune dysregulation, which can increase their susceptibility to periodontal disease (PD), elevating the risk of chronic oral inflammation, tissue damage, and oncogenesis. Persistent periodontitis may drive the development of oral squamous cell carcinoma (OSCC) through increased prevalence of pathogenic bacteria and elevated levels of inflammatory cytokines. In fact, our preliminary data show dysbiosis of the oral microbiome associated with PD. Furthermore, PD can be associated with inflammasome dysfunction, which can impact downstream production of cytokines. In PWH, these inflammatory processes may be exacerbated, fostering a pro-oncogenic microenvironment. This study aims to quantify levels of inflammasomes and inflammatory markers in PWH and evaluate their association with PD and OSCC risk.
Methods: Saliva and oral rinse samples, along with sociodemographic and clinical data, were collected from 202 virologically suppressed PWH. A comprehensive periodontal assessment was performed, and participants were categorized into four groups based on PD severity: none, mild, moderate, and severe. Protein levels of inflammasomes (NLRP3 and NLRC4) were quantified in saliva using ELISA, while cytokine concentrations (IL-1beta, IL-4, IL-6, IL-8, IL-10, IL-17A, and TNF-alpha) were quantified using ELLA. Statistical analyses were performed using R statistical software. Median values were compared using Mann-whitney or Krukal-wallis tests with post-hoc adjustment.
Results: Participants with PD exhibited significantly higher levels of IL-1beta (400 pg/mL vs 235 pg/mL, p<0.01), IL-6 (25.4 pg/mL vs 14.2 pg/mL, p<0.01), and IL-8 (798 pg/mL vs 549 pg/mL, p=0.04) while there was a trend for higher levels of IL-17 (2.01 pg/mL vs 1.50 pg/mL, p=0.05). In addition, IL-1beta was significantly higher in subjects with moderate (408 pg/mL, p=0.01) and severe PD (378 pg/mL, p=0.01) when compared to no PD (235 pg/mL). On the other hand, while there was no significant difference in the levels of NLRP3 and NLRC4 by PD status, people with severe PD (3.37 ng/mL) had significantly lower levels of NLRP3 when compared to moderate (5.83 ng/mL, p<0.01) or no PD (5.71 ng/mL, p=0.02).
Conclusion: There were increased levels of inflammatory cytokines, particularly IL-1B, and alterations to inflammasome levels according to PD severity, supporting the role of pyroptosis in the pathogenesis of PD. Chronic elevation of additional pyroptosis independent inflammatory cytokines and dysbiosis of the oral microbiome may contribute to a persistent inflammatory microenvironment associated with increased OSCC risk in PWH. These results highlight the importance of monitoring oral cytokine profiles as both biomarkers of disease progression and potential indicators of cancer risk in PWH.
利益披露 Disclosure
A. Y. Odeh, None..
J. L. Salgado Montilla, None..
R. F. Gonzalez-Garcia, None.